Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced a significant collaboration with Modulant Biosciences LLC. The two companies have signed a binding term sheet that grants Modulant exclusive global rights to develop and commercialize EL-22, a pioneering probiotic approach aimed at muscle preservation in livestock. This strategic partnership allows Northstrive to monetize its intellectual property in the animal health sector. If successfully developed and brought to market, EL-22 could become a long-term revenue-generating asset. The agreement also outlines that Modulant will share a portion of revenues from sublicensing and commercial activities with Northstrive, with specified royalty rates. The parties plan to finalize the definitive licensing agreement in the coming months, pending necessary approvals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。